Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14737856 | 1.00 | BCL2A1 (0.32) | BCL2A1CYP19A1 | |
| SCHEMBL17911018 | 0.88 | F2 (0.33) | — | |
| SCHEMBL4269678 | 0.88 | F2 (0.33) | — | |
| SCHEMBL15017631 | 0.86 | OAT (0.31) | — | |
| Hydrazine SCHEMBL22505628 | 0.81 | GPR35 (0.33) | CYP19A1 | |
| SCHEMBL398217 | 0.81 | GPR35 (0.34) | CYP19A1 | |
| SCHEMBL27827625 | 0.81 | ATM (0.32) | CYP19A1 | |
| SCHEMBL20241327 | 0.75 | ATM (0.39) | — | |
| SCHEMBL22229916 | 0.75 | ATM (0.39) | — | |
| SCHEMBL28681081 | 0.75 | ATM (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119119039-A | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | 阿克拉瑞斯治疗股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-111566095-B | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | 阿克拉瑞斯治疗股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11739086-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210284637-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2021-09-16 | — | — | US | disclosed |
| US-10981906-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| CN-111566095-A | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | 阿克拉瑞斯治疗股份有限公司 | 2020-08-21 | — | — | CN | disclosed |
| US-20190135808-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2019-05-09 | — | — | US | disclosed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| CN-104024258-B | Pyrrolopyrazine kinase inhibitors | 霍夫曼-拉罗奇有限公司 | 2017-02-15 | — | — | CN | disclosed |
| CN-104024258-A | Pyrrolopyrazine kinase inhibitors | HOFFMANN LA ROCHE | 2014-09-03 | — | — | CN | disclosed |
| EP-2763990-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981906-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | JAK3, JAK1, JAK2 | BCL2A1 3255/4885CYP19A1 1269/4885 |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | BCL2A1 3255/4885CYP19A1 1269/4885 |
| US-20210284637-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | BCL2A1 3255/4885CYP19A1 1269/4885 |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK1 | BCL2A1 2322/4885CYP19A1 2774/4885 |
| US-11739086-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | JAK3, JAK1, JAK2 | BCL2A1 3255/4885CYP19A1 1269/4885 |
| US-20190135808-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | BCL2A1 3255/4885CYP19A1 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.